Volume 20, Number 7—July 2014
Research
Borrelia miyamotoi sensu lato Seroreactivity and Seroprevalence in the Northeastern United States
Figure 1

Figure 1. Polyacrylamide gel electrophoresis purification (A) and Western blot analysis (B) of recombinant glycerophosphodiester phosphodiesterase (rGlpQ)A) Coomassie blue staining of purified Borrelia miyamotoi sensu lato rGlpQ (lane 1) and of Precision Plus Protein Prestained Standards (Bio-Rad, Laboratories, Hercules, CA, USA) (lane 2)B) Western blot analysis of Bmiyamotoi sensu lato–positive control mouse serum shows 39-kDa rGlpQ-specific band (arrow).
1Members of the Tick Borne Diseases Group are listed at the end of this article.
Page created: May 06, 2014
Page updated: May 06, 2014
Page reviewed: May 06, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.